Profile data is unavailable for this security.
About the company
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
- Revenue in USD (TTM)0.00
- Net income in USD-125.32m
- Incorporated2010
- Employees57.00
- LocationMind Medicine (MindMed) IncOne World Trade Center, Suite 8500NEW YORK 10007United StatesUSA
- Phone+1 (212) 220-6633
- Fax+1 (888) 848-3972
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurogene Inc | 0.00 | -39.03m | 575.55m | 91.00 | -- | 3.34 | -- | -- | -4.58 | -4.58 | 0.00 | 13.28 | 0.00 | -- | -- | 0.00 | -26.57 | -32.70 | -28.41 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
PepGen Inc | 0.00 | -80.33m | 578.97m | 64.00 | -- | 3.23 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 603.01m | 57.00 | -- | 3.05 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
Annexon Inc | 0.00 | -120.74m | 607.45m | 70.00 | -- | 2.02 | -- | -- | -1.46 | -1.46 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -42.15 | -44.06 | -44.99 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
iTeos Therapeutics Inc | 0.00 | -135.31m | 614.45m | 157.00 | -- | 1.13 | -- | -- | -3.78 | -3.78 | 0.00 | 15.10 | 0.00 | -- | -- | 0.00 | -19.93 | 5.84 | -20.88 | 7.02 | -- | -- | -- | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
GH Research PLC | 0.00 | -35.59m | 614.45m | 49.00 | -- | 2.81 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
Grail Inc | 100.18m | -1.49bn | 615.39m | 1.36k | -- | 0.1407 | -- | 6.14 | -56.16 | -56.16 | 3.77 | 140.84 | -- | -- | -- | 74,763.43 | -- | -47.45 | -- | -48.55 | 41.91 | -- | -1,488.21 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
Astria Therapeutics Inc | 0.00 | -81.63m | 622.17m | 59.00 | -- | 2.28 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -91.06m | 623.49m | 66.00 | -- | 2.63 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 629.98m | 19.00 | -- | 6.39 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
Verve Therapeutics Inc | 16.05m | -196.83m | 630.58m | 255.00 | -- | 1.08 | -- | 39.29 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Entrada Therapeutics Inc | 162.87m | 23.49m | 632.94m | 160.00 | 27.29 | 2.14 | 23.63 | 3.89 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Celcuity Inc | 0.00 | -73.45m | 637.79m | 55.00 | -- | 4.18 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Adaptive Biotechnologies Corp | 174.50m | -215.06m | 641.05m | 709.00 | -- | 2.33 | -- | 3.67 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.3238 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Larimar Therapeutics Inc | 0.00 | -45.08m | 643.76m | 42.00 | -- | 2.79 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Holder | Shares | % Held |
---|---|---|
Deep Track Capital LPas of 31 Mar 2024 | 6.67m | 9.46% |
Commodore Capital LPas of 31 Mar 2024 | 5.83m | 8.27% |
Driehaus Capital Management LLCas of 31 Mar 2024 | 2.55m | 3.61% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 2.15m | 3.05% |
Great Point Partners LLCas of 31 Mar 2024 | 2.00m | 2.84% |
Marshall Wace LLPas of 31 Mar 2024 | 2.00m | 2.84% |
Blackstone Alternative Asset Management LPas of 31 Mar 2024 | 1.25m | 1.77% |
Woodline Partners LPas of 31 Mar 2024 | 1.00m | 1.42% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 955.68k | 1.36% |
AWM Investment Co., Inc.as of 31 Mar 2024 | 833.00k | 1.18% |